Daniel Bran, GM of Accord Romania reveals that finding the right talent has been one of the most challenging and rewarding milestones in building the affiliate from the ground up. He shares his insights on what is driving Accord’s growth and how launching nearly 20 new products a year has been inducive to its performance. Bran describes the evolution of the company and how they have managed to become the leading generic hospital for the onco-haematology field thanks to their ambitious growth strategy within five years.
Accord provides one-third of the oncological treatments in Europe which makes it the continent's leading supplier of oncology products. In Romania, oncology and haematology are the affiliate’s flagship therapeutic areas
